Breast Cancer, Metastatic Breast Cancer
Conditions
Keywords
Breast Cancer, Metastatic Breast Cancer
Brief summary
This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine therapy in combination with palbociclib or alpelisib.
Detailed description
This is single-arm feasibility pilot study exploring whether a combined prolonged nightly fasting (POF) and exercise program could impact hyperglycemia and other adverse metabolic consequences of PI3 kinase inhibitors in women with metastatic breast cancer (MBC). Women who exercise regularly and who have lower levels of blood sugar and metabolic hormones like insulin have a lower risk of developing breast cancer. Some evidence also suggests that exercise and metabolism are related to cancer recurrence in women who are diagnosed with breast cancers that can be removed with surgery, but less is known about how exercise and metabolic factors are related to cancer progression in women whose cancer has advanced beyond the breast and underarm lymph nodes. This study is designed to look at the effects of exercise combined with prolonged nightly fasting (having a longer time between dinner and breakfast the next day), on blood sugar and hormones that control metabolism. This study looks to provide important information about whether making these kinds of changes is possible for women living with advanced breast cancer and will explore how making these changes effects blood sugar and hormone levels in women taking different kinds of treatments for advanced breast cancer. The research study procedures include screening for eligibility, a baseline visit to collect information about diet and exercise habits, a baseline blood draw, participation in a 12-week diet and exercise program, and a follow up visit and blood collection at the end of the diet and exercise program. Participants will be in this research study for up to 14-weeks, including the baseline and end of study visits to collect study measures. It is expected that about 30 people will take part in this research study
Interventions
BEHAVIORALProlonged Nightly Fasting
Restriction of consumption of calorie-containing food/drinks after 8pm
BEHAVIORALExercise
Personalized moderate-intensity, aerobic exercise and strength training
Sponsors
Dana-Farber Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of ER and/or PR+ metastatic or locally unresectable breast cancer * Postmenopausal (including concurrent use of ovarian suppression) * Initiating endocrine therapy in combination with: * Cohort 1: alpelisib * Cohort 2: palbociclib * Self-reported ability to walk two blocks * \> 18 years of age * Approval from treating oncologist, confirmed via email or in writing * Ability to read and understand English
Exclusion criteria
* Diagnosis of diabetes requiring medication * Engaging in \>90 minutes of moderate or vigorous physical activity per week
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of enrollment | 12 months | The primary objective is to evaluate the feasibility of the intervention. Feasibility will be defined by the rate of enrollment and the intervention will be considered feasible if at least 80% of planned participants are enrolled within 12 months of study activation. |
| Rate of adherence to prolonged overnight fasting (POF) intervention goals | 12 weeks | Feasibility will additionally be defined by participants achieving POF intervention goals on 70% of days by week 12. |
| Rate of adherence to exercise intervention goals | 12 weeks | Feasibility will also be defined by at least 70% of participants achieving 120 minutes of aerobic exercise plus 2 strength training classes per week by week 12. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in metabolic biomarkers between baseline and week 12 | 12 weeks | We will evaluate changes in fasting glucose, insulin, insulin resistance, hemoglobin A1c and other metabolic biomarkers in study participants between the baseline and end-of-intervention blood draws. |
| Change in quality of life and patient-reported outcome measures between baseline and week 12 | 12 weeks | Quality of life will be evaluated for participants at baseline and at the end of the intervention using the EORTC QLQ C-30, sleep quality will be assessed via the Pittsburgh Sleep Quality Index (PSQI). Additional patient reported outcomes include the PRO-CTCAE, the 7-Day Physical Activity Recall and the 24-Hour Dietary Recall. We will assess changes in these measures between baseline and week 12 for study participants. |
| Differences in changes in metabolic biomarkers by treatment group (palbociclib vs palbocilib) | 12 weeks | We will explore potential differences in changes in metabolic markers over the course of the 12-week POF and exercise intervention by treatment group (alpelisib vs palbociclib). |
Countries
United States
Outcome results
None listed